-
FDA Approves Biocon Biologics’ Bevacizumab Biosimilar
14 Apr 2025 16:57 GMT
… .S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a new … . It is indicated for the treatment of certain types of colorectal … ’s ZIRABEV™ (bevacizumab-bvzr) in June 2019, Amneal Pharmaceuticals’ ALYMSYS® (bevacizumab-maly) in …
-
BMS gets another FDA okay for Opdivo/Yervoy combo
14 Apr 2025 12:25 GMT
… open-label CheckMate-9DW trial.
In the trial, Opdivo/Yervoy- … for HCC again after the drug was pulled from the market … Imfinzi/Imjudo.
Tecentriq/bevacizumab also has a pretty strong … major feature of first-line treatment, with BMS' combination …
-
FDA Approves Avastin Biosimilar Agent, Jobevne
14 Apr 2025 06:48 GMT
The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon … of various combinations for the treatment of metastatic colorectal cancer, certain … Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate …
-
Krivak on PARP Inhibitors and Maintenance Therapy in Ovarian Cancer
14 Apr 2025 15:03 GMT
… nausea for 4 months.
Past medical, family, and social history
Polycystic … a phase 3 trial of olaparib/bevacizumab vs bevacizumab.4 It was … in these trials as well. Bevacizumab plus olaparib is the treatment arm. Bevacizumab is …
-
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
11 Apr 2025 20:11 GMT
… .S. Food and Drug Administration (FDA) approved Opdivo® ( … to BMS medicines during their treatment journey. BMS … and commercialization of pharmaceutical products. All statements … al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma …
-
FDA Approves Bevacizumab Biosimilar for Various Cancer Types
11 Apr 2025 18:41 GMT
… treatment of colon cancer.1
"The US FDA approval of JOBEVNE™ (bevacizumab … similarity to the reference drug. The package confirmed … Zirabev (bevacizumab-bvzr; Pfizer), Alymsys (bevacizumab-maly; Amneal Pharmaceuticals), Vegzelma (bevacizumab-adcd; …
-
FDA Approves Biocon’s Jobevne, Bevacizumab Biosimilar
11 Apr 2025 15:48 GMT
… and Drug Administration (FDA) for its cancer treatment biosimilar, Jobevne (bevacizumab-nwgd … a biosimilar to Avastin (bevacizumab), a widely used … high-quality, affordable treatment options.”
The approval … approvals in 2021.
Bevacizumab sales in the U …
-
Integration of scRNA-Seq and Bulk RNA-Seq Identifies Circadian Rhythm Disruption-Related Genes Associated with Prognosis and Drug Resistance in Colorectal Cancer Patients
11 Apr 2025 12:56 GMT
… tool for assessing responses to bevacizumab and Adoptive Cell Transfer (ACT … and non-responders (NR) to bevacizumab and Adoptive Cell Transfer (ACT … insights into treatment, particularly for immunotherapy.19 Chronotherapy, which optimizes drug administration …
-
FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer
11 Apr 2025 08:49 GMT
… Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd … all stakeholders to bring more treatment options to patients.”
Biocon Biologics … and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson …
-
Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE
11 Apr 2025 07:23 GMT
… Drug Administration (USFDA) for JOBEVNE, a biosimilar version of Bevacizumab … Biosimilar
The newly approved drug, JOBEVNE (bevacizumab-nwgd), is a … . “The U.S. FDA approval of JOBEVNE is a … opportunity, with sales of bevacizumab approximating USD 2 billion …
About
© 1995-2025